Auransa

Palo Alto, California, United States

Biotech AI / ML Drug Discovery Cancer Care

We are a clinical-stage, AI-native biopharma that mines massive data for therapeutic gold to raise the standard of cancer care. Our platform uses AI and available, heterogenous human disease data to uncover novel drug candidates for the most responsive patients, leading to smarter drug discovery that maximizes clinical trial success. We are currently focused on advancing better therapies for cancers and cancer-related diseases.

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out Auransa on @MedStartr Today #CancerCare #OncologicalDiseases #DrugDevelopment #Biotech #AIML #DrugDiscovery #MedMo #MedStartrVentures

https://www.medstartr.ai/s/IjOSxCGJqWM

Get Involved in Auransa

🏢Is this your company? Claim This Profile

Join MedStartr to verify with your work email and edit this profile

Company Info

Founded: 2014
Website: www.auransa.com/

Disease Areas

Cancer Care Oncological Diseases Drug Development

Technologies

AI-native PlatformAI/Machine LearningBig DataDrug Development

🌐Website

What do you think of Auransa?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.